{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T21:13:02Z","timestamp":1787605982835,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100022720","name":"Health Bureau","doi-asserted-by":"publisher","award":["CID-HKU2-12"],"award-info":[{"award-number":["CID-HKU2-12"]}],"id":[{"id":"10.13039\/100022720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022720","name":"Health Bureau","doi-asserted-by":"publisher","award":["CID-HKU2-12"],"award-info":[{"award-number":["CID-HKU2-12"]}],"id":[{"id":"10.13039\/100022720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["T11-705\/21-N"],"award-info":[{"award-number":["T11-705\/21-N"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89043-8","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:00:31Z","timestamp":1739624431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality"],"prefix":"10.1038","volume":"15","author":[{"given":"Jialiang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok Fai","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Ho Yin","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin John","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"89043_CR1","unstructured":"World Health Organization COVID-19 dashboard. Accessed on 24 February. Available online at: https:\/\/covid19.who.int (2024)."},{"key":"89043_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-022-05522-2","volume":"613","author":"W Msemburi","year":"2022","unstructured":"Msemburi, W. et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613, 130\u2013137 (2022).","journal-title":"Nature"},{"issue":"1","key":"89043_CR3","doi-asserted-by":"publisher","first-page":"e2252684","DOI":"10.1001\/jamanetworkopen.2022.52684","volume":"6","author":"S Park","year":"2023","unstructured":"Park, S. et al. Unreported SARS-CoV-2 home testing and test positivity. JAMA Net. Open. 6(1), e2252684\u2013e2252684 (2023).","journal-title":"JAMA Net. Open."},{"key":"89043_CR4","unstructured":"Statistics on 5th Wave of COVID-19. Accessed on 24 February. Available online at: https:\/\/www.coronavirus.gov.hk\/pdf\/5th_wave_statistic s\/5th_wave_statistics_20230129.pdf. (2024)."},{"issue":"11","key":"89043_CR5","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.3390\/v14112519","volume":"14","author":"S-C Wong","year":"2022","unstructured":"Wong, S.-C. et al. Evolution and Control of COVID-19 Epidemic in Hong Kong. Viruses. 14(11), 2519 (2022).","journal-title":"Viruses."},{"key":"89043_CR6","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.lanwpc.2023.100969","volume":"43","author":"B Yang","year":"2024","unstructured":"Yang, B. et al. Comparison of control and transmission of COVID-19 across epidemic waves in Hong Kong: an observational study. Lancet Reg. Health. Western Pacific. 43, 100969 (2024).","journal-title":"Lancet Reg. Health. Western Pacific."},{"issue":"1","key":"89043_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","volume":"19","author":"N Murakami","year":"2023","unstructured":"Murakami, N. et al. Therapeutic advances in COVID-19. Nat. Rev. Nephrol. 19(1), 38\u201352 (2023).","journal-title":"Nat. Rev. Nephrol."},{"issue":"15","key":"89043_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New Engl. J. Med. 386(15), 1397\u20131408 (2022).","journal-title":"New Engl. J. Med."},{"issue":"6","key":"89043_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"BA Jayk","year":"2022","unstructured":"Jayk, B. A. et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New Engl. J. Med. 386(6), 509\u2013520 (2022).","journal-title":"New Engl. J. Med."},{"issue":"10359","key":"89043_CR10","first-page":"1213","volume":"400","author":"CKH Wong","year":"2022","unstructured":"Wong, C. K. H. et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet (British edition). 400(10359), 1213\u20131222 (2022).","journal-title":"Lancet (British edition)."},{"issue":"10359","key":"89043_CR11","first-page":"1175","volume":"400","author":"C Burdet","year":"2022","unstructured":"Burdet, C. & Ader, F. Real-world effectiveness of oral antivirals for COVID-19. Lancet (British edition). 400(10359), 1175\u20131176 (2022).","journal-title":"Lancet (British edition)."},{"key":"89043_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae163","author":"YM Mesfin","year":"2024","unstructured":"Mesfin, Y. M. et al. Effectiveness of nirmatrelvir\/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. J. Antimicro. Chem. https:\/\/doi.org\/10.1093\/jac\/dkae163 (2024).","journal-title":"J. Antimicro. Chem."},{"key":"89043_CR13","unstructured":"US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. Accessed on June 30, Available online at: https:\/\/www.fda.gov\/media\/155054\/download (2022)."},{"key":"89043_CR14","unstructured":"GovHK. First shipment of COVID-19 oral drug Paxlovid distributed to HA for application (with photos). Accessed on 20 December. Available online at: https:\/\/www.info.gov.hk\/gia\/general\/202203\/15\/P2022031500280.htm."},{"key":"89043_CR15","unstructured":"GovHK. Introduction of new drugs for treating Coronavirus Disease. Accessed on 20 December 2024. Available online at: https:\/\/www.info.gov.hk\/gia\/general\/202202\/23\/P2022022300303.htm?fontSize=1. (2019)."},{"key":"89043_CR16","unstructured":"The Hospital Authority. Latest information on two types of COVID-19 oral antiviral drugs. Accessed on 20 December. Available online at: https:\/\/www.ha.org.hk\/haho\/ho\/pad\/266364en.pdf. (2024)."},{"issue":"38","key":"89043_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","volume":"70","author":"WH Self","year":"2021","unstructured":"Self, W. H. et al. Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021. MMWR. Morb. Mortal. Weekly Rep. 70(38), 1337\u20131343 (2021).","journal-title":"MMWR. Morb. Mortal. Weekly Rep."},{"issue":"10","key":"89043_CR18","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","volume":"22","author":"ME McMenamin","year":"2022","unstructured":"McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect. Dis. 22(10), 1435\u20131443 (2022).","journal-title":"Lancet Infect. Dis."},{"issue":"19","key":"89043_CR19","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New Engl. J. Med. 385(19), 1761\u20131773 (2021).","journal-title":"New Engl. J. Med."},{"key":"89043_CR20","first-page":"e067873","volume":"375","author":"A Israel","year":"2021","unstructured":"Israel, A. et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ (Online). 375, e067873\u2013e067873 (2021).","journal-title":"BMJ (Online)."},{"key":"89043_CR21","unstructured":"The Government of the Hong Kong Special Administrative Region. SFH Authorises COVID-19 Vaccine by Fosun Pharma\/BioNTech for Emergency Use in Hong Kong. Accessed on 24 February. Available online at: https:\/\/www.info.gov.hk\/gia\/general\/202101\/25\/P2021012500829.htm. (2024)."},{"key":"89043_CR22","unstructured":"The Government of the Hong Kong Special Administrative Region. SFH Authorises COVID-19 Vaccine by Sinovac for Emergency use in Hong Kong. Accessed on 24 February. Available online at: https:\/\/www.info.gov.hk\/gia\/general\/202102\/18\/P2021021800495.htm. (2024)."},{"issue":"24","key":"89043_CR23","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning immunity after the BNT162b2 Vaccine in Israel. New Engl. J. Med. 385(24), e85\u2013e85 (2021).","journal-title":"New Engl. J. Med."},{"issue":"4","key":"89043_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Duration of protection against Mild and severe disease by Covid-19 Vaccines. New Engl. J. Med. 386(4), 340\u2013350 (2022).","journal-title":"New Engl. J. Med."},{"key":"89043_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2022.03.028","volume":"119","author":"JL Suah","year":"2022","unstructured":"Suah, J. L. et al. Waning COVID-19 Vaccine effectiveness for BNT162b2 and CoronaVac in Malaysia: An observational study. Int. J. Infect. Dis. 119, 69\u201376 (2022).","journal-title":"Int. J. Infect. Dis."},{"issue":"8","key":"89043_CR26","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/infdis\/jiac360","volume":"226","author":"B Yang","year":"2022","unstructured":"Yang, B. et al. Effectiveness of CoronaVac and BNT162b2 vaccines against severe acute respiratory syndrome Coronavirus 2 Omicron BA 2 infections in Hong Kong. J. Infect. Dis. 226(8), 1382\u20131384 (2022).","journal-title":"J. Infect. Dis."},{"issue":"10","key":"89043_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 Vaccine in Chile. New Engl. J. Med. 385(10), 875\u2013884 (2021).","journal-title":"New Engl. J. Med."},{"issue":"5","key":"89043_CR28","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S1473-3099(24)00150-6","volume":"24","author":"D-Y Lin","year":"2024","unstructured":"Lin, D.-Y. et al. Effectiveness of XBB 1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA. Lancet Infect. Dis. 24(5), e278\u2013e280 (2024).","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"89043_CR29","first-page":"70","volume":"30","author":"YYH Cheung","year":"2024","unstructured":"Cheung, Y. Y. H. et al. Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19. Hong Kong. Emerging Infect. Dis. 30(1), 70\u201378 (2024).","journal-title":"Hong Kong. Emerging Infect. Dis."},{"key":"89043_CR30","doi-asserted-by":"publisher","first-page":"107012","DOI":"10.1016\/j.ijid.2024.107012","volume":"143","author":"YYH Cheung","year":"2024","unstructured":"Cheung, Y. Y. H. et al. Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach. Int. J. Infect. Dis. 143, 107012\u2013107012 (2024).","journal-title":"Int. J. Infect. Dis."},{"issue":"3","key":"89043_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/sim.3783","volume":"29","author":"YB Cheung","year":"2010","unstructured":"Cheung, Y. B. et al. Estimation of intervention effects using first or multiple episodes in clinical trials: The Andersen-Gill model re-examined. Stat. Med. 29(3), 328\u2013336 (2010).","journal-title":"Stat. Med."},{"issue":"17","key":"89043_CR32","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/sim.7319","volume":"36","author":"J Xu","year":"2017","unstructured":"Xu, J. et al. Semiparametric estimation of time-varying intervention effects using recurrent event data. Stat. Med. 36(17), 2682\u20132696 (2017).","journal-title":"Stat. Med."},{"issue":"2","key":"89043_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","volume":"29","author":"JJ Lau","year":"2023","unstructured":"Lau, J. J. et al. Real world COVID-19 vaccine effectiveness against the Omicron BA 2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 29(2), 348\u2013357 (2023).","journal-title":"Nat. Med."},{"issue":"1","key":"89043_CR34","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1038\/s41467-022-31469-z","volume":"13","author":"L Rennert","year":"2022","unstructured":"Rennert, L. et al. Effectiveness and protection duration of Covid-19 Vaccines and previous infection against any SARS-CoV-2 infection in young adults. Nat. Commun. 13(1), 3946\u20133948 (2022).","journal-title":"Nat. Commun."},{"issue":"9","key":"89043_CR35","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/sim.10049","volume":"43","author":"YB Cheung","year":"2024","unstructured":"Cheung, Y. B. et al. Estimation of trajectory of protective efficacy in infectious disease prevention trials using recurrent event times. Stati. Med. 43(9), 1759\u20131773 (2024).","journal-title":"Stati. Med."},{"issue":"6","key":"89043_CR36","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s15010-023-02028-5","volume":"51","author":"P Bertuccio","year":"2023","unstructured":"Bertuccio, P. et al. The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study. Infect. 51(6), 1633\u20131644 (2023).","journal-title":"Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89043-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:00:41Z","timestamp":1739624441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89043-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89043"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89043-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche and Sanofi Pasteur. The other authors report no other potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5640"}}